<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatments for male infertility</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatments for male infertility</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatments for male infertility</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley D Anawalt, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 28, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3500599085"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>In the United States, infertility in a couple is defined as the inability to achieve conception despite one year of frequent, unprotected intercourse  (<a class="graphic graphic_figure graphicRef80057" href="/z/d/graphic/80057.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. This topic provides an overview of the treatments of male infertility. The causes and approach to evaluation of male infertility are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/7453.html" rel="external">"Approach to the male with infertility"</a> and  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility"</a>.)</p><p class="headingAnchor" id="H908110143"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>In studies of untreated couples pursuing pregnancy, 50 percent conceived within three months, 70 percent within six months, and 85 percent within 12 months  (<a class="graphic graphic_figure graphicRef80057" href="/z/d/graphic/80057.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. Up to 50 percent of young, healthy couples who fail to conceive in the first 12 months will conceive in the next 12 months [<a href="#rid2">2</a>]. Therefore, it might be appropriate to delay invasive reproductive techniques in couples where the female partner has normal menstrual cycles, the male partner has normal semen analyses, and neither partner has an identifiable cause of infertility.</p><p class="headingAnchor" id="H1271126282"><span class="h2">Categories of male infertility</span><span class="headingEndMark"> — </span>The causes of male infertility can be divided into four main areas  (<a class="graphic graphic_table graphicRef54356" href="/z/d/graphic/54356.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine and systemic disorders </strong>(usually related to secondary [hypogonadotropic] hypogonadism) – 2 to 5 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary testicular defects in spermatogenesis</strong> – 65 to 80 percent, of which the majority have idiopathic dysspermatogenesis, an isolated defect in spermatogenesis without an identifiable cause.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sperm transport disorders</strong> – 5 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic male infertility</strong> – 10 to 20 percent. Idiopathic male infertility should be distinguished from idiopathic dysspermatogenesis. Idiopathic male infertility describes an infertile man with a normal semen analysis and no apparent cause for infertility, whereas infertile men with idiopathic dysspermatogenesis have abnormal semen analyses.</p><p></p><p class="headingAnchor" id="H2666965963"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Treatment of male infertility should be guided by the following general principles as well as by the specific causes of the infertility:</p><p class="headingAnchor" id="H1116715925"><span class="h3">Concurrent male and female infertility</span><span class="headingEndMark"> — </span>Treatment of male infertility involves the couple. The distribution of male and female causes among infertile couples has not been well defined. In a 1982 to 1985 World Health Organization (WHO) multicenter study, 20 percent of cases were attributed to male factors, 38 percent to female factors, 27 percent had causal factors identified in both partners, and 15 percent could not be satisfactorily attributed to either partner [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/7396.html" rel="external">"Overview of infertility"</a>.)</p><p>It is essential that the female partner be thoroughly investigated and treated while the male partner is being evaluated. Problems in the female partner, such as anovulation or irregular ovulation, endometriosis, and tubal obstruction, should be simultaneously addressed with or before treatment of the male partner. Treatment of the female partner can often compensate for male factor subfertility and result in pregnancy without treatment of the male. (See  <a class="medical medical_review" href="/z/d/html/7396.html" rel="external">"Overview of infertility"</a>.)</p><p class="headingAnchor" id="H2833478835"><span class="h3">Documentation of treatment efficacy</span><span class="headingEndMark"> — </span>Pregnancy often occurs independently from treatment in apparently infertile young couples. Many medical and surgical procedures have been reported to improve male fertility only to be shown subsequently to be ineffective. The two principal reasons for the large number of initially promising, but ultimately misleading, reports are the use of semen quality, instead of pregnancy, as the criterion of success and the failure to include a control group in the trial [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2813194680"><span class="h3">Is the patient hypogonadal?</span><span class="headingEndMark"> — </span>Assessment of the function of the hypothalamic-pituitary-testicular axis is helpful in determination of the potential role of medical therapy to restore fertility in the small minority of men whose infertility is due to secondary (hypogonadotropic) hypogonadism. Assessment of this axis is also important to identify the subset of men that have combined deficiencies of sperm and <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> production. Men with testosterone deficiency may benefit from testosterone replacement therapy, but it is important to recognize that testosterone therapy will <strong>suppress</strong> spermatogenesis. (See  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility"</a> and  <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a> and  <a class="medical medical_review" href="/z/d/html/7459.html" rel="external">"Causes of primary hypogonadism in males"</a>.)</p><p>The distinction between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism is important because medical therapy might be useful in restoring fertility in men with secondary (hypogonadotropic) hypogonadism, but it will not be useful in primary (hypergonadotropic) hypogonadism. Men with primary (hypergonadotropic) hypogonadism generally require assisted reproductive technology (ART) such as surgical testicular sperm extraction (TESE) and intracytoplasmic sperm injection (ICSI) into the female partner's egg in order to conceive children. (See <a class="local">'Assisted reproductive technologies'</a> below and <a class="local">'Retrieval of sperm'</a> below.)</p><p class="headingAnchor" id="H4046538618"><span class="h3">Eugonadal, infertile men</span><span class="headingEndMark"> — </span>Eugonadal, infertile men (with normal serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a>, follicle-stimulating hormone [FSH], and luteinizing hormone [LH] concentrations) might have causes that can be treated surgically to enhance or restore fertility (eg, surgical excision of a large varicocele or surgical correction of ejaculatory duct obstruction). However, eugonadal, infertile men, like men with primary (hypergonadotropic) hypogonadism, often must be treated with ART in order to conceive. (See <a class="local">'Surgical repair of varicocele'</a> below and <a class="local">'Obstruction of epididymis or ejaculatory duct'</a> below and <a class="local">'Assisted reproductive technologies'</a> below.)</p><p class="headingAnchor" id="H3093032378"><span class="h3">Use of assisted reproductive technologies</span><span class="headingEndMark"> — </span>The development of ART has allowed many couples with male factor infertility to conceive. Because ART may be effective in any man with evidence of spermatogenesis (even microscopic nests of sperm visible only on testicular histology, eg, in men with Klinefelter syndrome), ART may useful in the treatment of many causes of male infertility. Thus, we discuss ART in a separate section from categorical causes of male infertility. (See <a class="local">'Assisted reproductive technologies'</a> below.)</p><p class="headingAnchor" id="H1647695277"><span class="h1">APPROACH BASED UPON DIAGNOSIS</span></p><p class="headingAnchor" id="H2625265335"><span class="h2">Endocrine and systemic disorders</span><span class="headingEndMark"> — </span>Most endocrine and systemic disorders that cause male infertility are associated with secondary (hypogonadotropic) hypogonadism. Treatment of the underlying endocrine or systemic disorder may result in eugonadism and improved spermatogenesis and fertility. If treatment of the underlying endocrine or systemic disorder does not normalize serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> and improve spermatogenesis and fertility, then gonadotropin replacement therapy might be beneficial.</p><p>For example, if a man with a prolactin-secreting macroadenoma has persistent secondary (hypogonadotropic) hypogonadism and azoospermia 6 to 12 months after appropriate treatment of the prolactin macroadenoma, gonadotropin replacement therapy should be considered if conception is desired. In this example, the underlying pituitary disease has induced hypogonadotropism that is unlikely to resolve. (See <a class="local">'Hyperprolactinemia'</a> below and  <a class="medical medical_review" href="/z/d/html/7463.html" rel="external">"Induction of fertility in males with secondary hypogonadism"</a>.)</p><p class="headingAnchor" id="H3881414336"><span class="h3">Secondary (hypogonadotropic) hypogonadism: Induction of spermatogenesis</span><span class="headingEndMark"> — </span>Specific treatments, including gonadotropin replacement therapy, are available for men whose infertility results from secondary (hypogonadotropic) hypogonadism. Secondary hypogonadism is present if the serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration is low and serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations are low or inappropriately normal. (See  <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a>.)</p><p>Normal spermatogenesis takes approximately three months. As a result, a rise in sperm concentrations, as measured by semen analysis, usually does not occur for at least three and sometimes six months or more with any medical treatment of secondary (hypogonadotropic) hypogonadism. With effective treatment of secondary hypogonadism, time to conception may occur within six months, but may take two or more years. Induction of spermatogenesis in men with secondary hypogonadism is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7463.html" rel="external">"Induction of fertility in males with secondary hypogonadism"</a>.)</p><p class="headingAnchor" id="H1832482309"><span class="h3">Hyperprolactinemia</span><span class="headingEndMark"> — </span>If secondary (hypogonadotropic) hypogonadism results from hyperprolactinemia, the hypogonadism might be corrected and fertility restored by lowering the serum prolactin concentration.</p><p class="bulletIndent1"><span class="glyph">●</span>If the hyperprolactinemia results from a medication, that medication should be discontinued, if possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the hyperprolactinemia results from a lactotroph adenoma, the adenoma should be treated with a dopamine agonist, such as <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">cabergoline</a> or <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a>. (See  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a>.)</p><p></p><p>In some patients who have a prolactin-secreting macroadenoma, secondary (hypogonadotropic) hypogonadism might result from permanent damage to the gonadotroph cells by the mass effect of the adenoma. Lowering the serum prolactin concentration and shrinking the adenoma in this setting may not be sufficient to increase the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration and sperm count. Thus, if the serum testosterone concentration does not increase to normal within 6 to 12 months of the serum prolactin being reduced to normal, gonadotropin replacement treatment should be instituted if fertility is desired. (See  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia", section on 'Macroadenomas'</a> and  <a class="medical medical_review" href="/z/d/html/7463.html" rel="external">"Induction of fertility in males with secondary hypogonadism"</a>.)</p><p class="headingAnchor" id="H2389991796"><span class="h2">Primary testicular defects in sperm production</span><span class="headingEndMark"> — </span>Primary testicular defects in sperm production with or without <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> deficiency are the most common causes of male infertility.</p><p>Infertility due to primary testicular defects resulting in decreased production of normal sperm can divided into three categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Low serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> and high serum FSH and LH concentrations</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> and isolated elevation of serum FSH concentration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> and gonadotropins</p><p></p><p class="headingAnchor" id="H4083694573"><span class="h3">Low serum T, elevated FSH and LH</span><span class="headingEndMark"> — </span>Men with primary (hypergonadotropic) hypogonadism have low serum total <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> (T) and high luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The seminiferous tubules in these men are severely damaged, so most patients are azoospermic. There are no known effective medical therapies for these men, and success rates with assisted reproductive technology (ART) are low compared with men with other infertility diagnoses. Obtaining testicular tissue for histologic examination helps to determine whether such men can conceive via ART [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H1930777975"><span class="h3">Normal serum T and LH, high FSH</span><span class="headingEndMark"> — </span>Infertile men with isolated elevation of serum follicle-stimulating hormone (FSH) and normal <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> (T) and luteinizing hormone (LH) concentrations have variable degrees of dysspermatogenesis, resulting in a spectrum of findings, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Low to low-normal concentrations of sperm in the ejaculate </p><p class="bulletIndent1"><span class="glyph">●</span>Sperm visible only on testicular biopsies</p><p class="bulletIndent1"><span class="glyph">●</span>No sperm on testicular biopsy</p><p></p><p>Many of these men have sperm present in the ejaculate or in a testicular biopsy that can be used for ART.</p><p class="headingAnchor" id="H77716003"><span class="h3">Normal serum T, normal LH and FSH</span></p><p class="bulletIndent1"><span class="glyph">●</span>Most infertile men who have normal serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> (T) concentrations, normal serum gonadotropin (luteinizing hormone [LH] and follicle-stimulating hormone [FSH]) concentrations and a primary defect in spermatogenesis have sperm in the ejaculate, but the numbers of sperm with normal motility and/or normal morphology are low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Men with normal serum T and normal LH and FSH who also have azoospermia should be evaluated for ejaculatory duct obstruction. (See <a class="local">'Obstruction of epididymis or ejaculatory duct'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For therapeutic purposes, clinicians may consider infertile men with oligozoospermia and normal serum hormones in the same category as men with idiopathic infertility (ie, men with normal semen analyses and normal serum hormones). There is no clearly effective medical therapy for these men. Strategies include continuation of attempts at natural conception or ART. (See <a class="local">'Assisted reproductive technologies'</a> below.)</p><p></p><p class="headingAnchor" id="H891461469"><span class="h3">Treatment options based upon presence of sperm</span><span class="headingEndMark"> — </span>Each of the hormone categories described above can be further divided based on whether sperm are seen in the ejaculate or in a testicular biopsy.</p><p class="headingAnchor" id="H1008715690"><span class="h4">Sperm in the ejaculate</span><span class="headingEndMark"> — </span>When there are sperm in the ejaculate, the options include continued attempts at conception through vaginal intercourse or ART. However, a 2016 Cochrane review found no evidence of an improvement in live birth rate with ART in infertile couples due to male factor infertility (decreased sperm in the ejaculate) [<a href="#rid7">7</a>]. On the other hand, some experts suggest that ART decreases the time to conception and live births for some couples with male factor oligozoospermia due to dysspermatogenesis [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H911974193"><span class="h4">Spermatids or mature spermatozoa seen only in testicular biopsies</span><span class="headingEndMark"> — </span>ART is effective for some men with spermatids or mature spermatozoa seen only in testicular biopsies. Forty to 50 percent of men with primary (hypergonadotropic) hypogonadism and azoospermia on semen analysis have spermatids or mature spermatozoa on testicular biopsies that might be surgically retrievable and used to fertilize the female partner's oocytes using ART (see <a class="local">'Retrieval of sperm'</a> below). However, there are important genetic implications of using sperm from men with primary (hypergonadotropic) hypogonadism or men with severe oligozoospermia [<a href="#rid9">9</a>]. (See <a class="local">'Retrieval of sperm'</a> below and <a class="local">'Genetic counseling and testing'</a> below.)</p><p class="headingAnchor" id="H1865711273"><span class="h4">No sperm seen in testicular biopsies</span><span class="headingEndMark"> — </span>For men with azoospermia due to a primary testicular defect in spermatogenesis, there is no therapy available to enable conception.</p><p class="headingAnchor" id="H1988972121"><span class="h3">Unproven therapies</span><span class="headingEndMark"> — </span>Clinicians should be aware of several unproven medical and surgical therapies that are offered as treatments to infertile men with oligozoospermia and normal serum hormones and to men with idiopathic infertility:</p><p class="headingAnchor" id="H2254926830"><span class="h4">Surgical repair of varicocele</span><span class="headingEndMark"> — </span>We suggest varicocele repair only in infertile men with abnormal semen analyses and large, grade 3 varicoceles. Surgical repair is also reasonable in men (with or without infertility) with large varicoceles causing symptoms [<a href="#rid10">10-12</a>]. We do not recommend varicocele surgery in infertile men with small, nonpalpable varicoceles.</p><p>Data on the efficacy of varicocele repair for improving fertility have been conflicting. However, a 2012 meta-analysis of 10 trials in 894 men reported improved pregnancy rates with varicocele repair (surgical ligation or radiological embolization of the internal spermatic vein) when compared with expectant management [<a href="#rid12">12</a>]. The number needed to treat for one additional pregnancy was 17. However, live birth rates were not reported as the primary outcome in any of the trials, and the quality of the evidence was very low.</p><p>We also do not recommend repair in men with severe oligozoospermia or azoospermia, high serum FSH concentrations, and small testes, as these men have severe germ cell damage and a lower likelihood of fertility after varicocele repair.</p><p class="headingAnchor" id="H77329956"><span class="h4">Treatment of leukospermia</span><span class="headingEndMark"> — </span>We recommend against antibiotic treatment for leukospermia. We also recommend against treatment with nonsteroidal antiinflammatory drugs (NSAIDs) because there are insufficient data that they improve male fertility and there are potential adverse effects (including peptic ulcer diseases and renal injury).</p><p>Some infertile men are diagnosed with infections of the urogenital tract based on the presence of increased leukocytes (&gt;1 million per mL) in the semen [<a href="#rid13">13</a>]. These patients are often labeled as having chronic prostatitis, but specific organisms are rarely identified. The effect of chlamydia infections on semen quality and infertility remains controversial [<a href="#rid14">14</a>]. Some experts treat infertile men with leukospermia with antibiotics, but clinical trials have failed to demonstrate a benefit [<a href="#rid2">2,15,16</a>]. Similarly, because inflammation is associated with increased reactive oxidative species, some experts recommend NSAIDs, mast cell blockers, or antioxidants (eg, <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>) to improve sperm quality for men with asymptomatic leukospermia [<a href="#rid15">15,17</a>]. Short-term vitamin E therapy has also been tried, but its efficacy is unproven [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H1202676852"><span class="h4">Medical therapies to increase circulating gonadotropin concentrations</span><span class="headingEndMark"> — </span>We recommend against using <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a>, aromatase inhibitors, or gonadotropin therapy for idiopathic dysspermatogenesis or idiopathic male infertility.</p><p>Therapies to increase circulating gonadotropins (and maximally stimulate spermatogenesis) include <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate, aromatase inhibitors, recombinant human follicle-stimulating hormone (rhFSH). The data for clomiphene do not support its use in the treatment of male fertility, and the data for aromatase inhibitors are restricted to case reports and small, low-quality studies [<a href="#rid18">18-34</a>].</p><p>A 2013 Cochrane meta-analysis of six randomized trials of gonadotropin therapy in men with idiopathic infertility reported higher pregnancy rates in the gonadotropin-treated group compared with the placebo group [<a href="#rid26">26</a>]. However, treatment protocols and follow-up periods were variable, and the quality of the evidence was very low. Larger trials are needed before conclusions about the efficacy of this approach can be made.</p><p class="headingAnchor" id="H3159938200"><span class="h4">Lifestyle changes</span><span class="headingEndMark"> — </span>We suggest healthy lifestyle practices for infertile men. Although there is little evidence that lifestyle changes improve fertility, there is inferential evidence that avoiding tobacco, marijuana, excessive alcohol intake, and obesity might be useful for optimizing spermatogenesis. Although increased scrotal heat may impair spermatogenesis, it is not necessary for men to avoid tight fitting underwear or to avoid saunas or hot baths [<a href="#rid27">27,28,35-37</a>]. (See  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility"</a> and  <a class="medical medical_review" href="/z/d/html/7453.html" rel="external">"Approach to the male with infertility"</a>.)</p><p class="headingAnchor" id="H489525311"><span class="h4">Dietary supplements: Fish oil</span><span class="headingEndMark"> — </span>In addition to adopting healthy lifestyle practices, some men with infertility use fish oil supplements as a treatment strategy. Based upon available evidence, we do not suggest using fish oil as a therapy for male infertility. Placebo-controlled studies of infertile men with fish oil supplements (which contain the omega-3 fatty acids docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA] have demonstrated inconsistent results on sperm parameters in infertile men [<a href="#rid38">38-40</a>].</p><p>Additional data come from a cross-sectional study of healthy, young men presenting for a fitness examination for potential military service [<a href="#rid41">41</a>]. Those who reported fish oil supplement use in the 60 days prior to the examination had slightly higher average testicular volume (+1.5 mL [95% CI 0.2-2.8]) and semen volume (+0.64 mL [95%CI 0.15-1.12] and compared with those who did not use any fish oil supplements. Men taking fish oil supplements tended to have slightly higher average total sperm counts. However, these differences in testicular volume, seminal fluid volume, and total sperm counts were small and minimal clinical significance; average testicular volume, seminal fluid volume, and sperm counts were well within the normal range in men who did not report taking fish oil supplements. Finally, the men who took fish oil supplements self-reported higher levels of health and fewer febrile episodes; it cannot be determined whether fish oil supplements are causally related to these improvements or due to some other confounding factor in this study.</p><p class="headingAnchor" id="H634059905"><span class="h2">Sperm transport disorders</span><span class="headingEndMark"> — </span>Decreased sperm transportation to the female partner's vagina include infrequent vaginal sexual intercourse, erectile dysfunction, ejaculatory disorders (eg, retrograde ejaculation), and obstruction of epididymis or ejaculatory duct. All disorders of sperm transportation may be treated with ART, but some can be treated with specific therapies.</p><p class="headingAnchor" id="H1459681513"><span class="h3">Sexual disorders</span><span class="headingEndMark"> — </span>Fertility may optimized with vaginal intercourse at least twice weekly [<a href="#rid42">42</a>]. Severe erectile dysfunction should be treated. (See  <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">"Treatment of male sexual dysfunction", section on 'Erectile dysfunction'</a>.)</p><p class="headingAnchor" id="H1881673570"><span class="h3">Retrograde ejaculation</span><span class="headingEndMark"> — </span>A 2015 systematic review concluded that oral sympathomimetics improve antegrade ejaculation in many men with complete retrograde ejaculation [<a href="#rid43">43</a>]. However, there are very few data on the effectiveness of medical therapy to increase live birth rates in couples with male factor infertility related to retrograde ejaculation [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/7469.html" rel="external">"Treatment of male sexual dysfunction", section on 'Ejaculatory disorders'</a>.)</p><p class="headingAnchor" id="H1687707798"><span class="h3">Obstructive azoospermia</span><span class="headingEndMark"> — </span>Obstructive azoospermia can be the result of several processes. Most causes of obstructive azoospermia can be treated with surgical correction or with ART. (See  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility"</a>.)</p><p class="headingAnchor" id="H2978784862"><span class="h4">Obstruction of epididymis or ejaculatory duct</span><span class="headingEndMark"> — </span>Azoospermia due to obstruction in the epididymis can be treated by microsurgical end-to-end anastomosis of the epididymal duct to epididymal duct or to the vas deferens. The results depend on site of the obstruction and the experience and skill of the operator. Retrospective studies have demonstrated pregnancy rates of 20 to 30 percent after surgical anastomosis [<a href="#rid45">45</a>].</p><p>The appearance of spermatozoa after re-anastomosis for vasectomy reversal exceeds 90 percent, with pregnancy in over 50 percent [<a href="#rid46">46,47</a>]. The success rate depends upon the duration between vasectomy and the reversal procedure; in general, the longer after vasectomy, the poorer the pregnancy rate [<a href="#rid47">47,48</a>]. For a man with a history of vasectomy, ART with sperm retrieval with intracytoplasmic sperm injection (ICSI) is also an option. Given the continual improvements in ART, vasectomy reversal and ART should be discussed with the couple with male factor infertility due to vasectomy [<a href="#rid49">49,50</a>]. For example, an older couple that includes a male partner who underwent vasectomy many years ago might opt for ART.</p><p class="headingAnchor" id="H3013474666"><span class="h4">Congenital bilateral absence of the vasa deferentia</span><span class="headingEndMark"> — </span>For men with congenital bilateral absence of the vas deferentia, the most extreme form of "obstruction" of transportation of sperm, ART with sperm retrieval is the only option for conception. (See <a class="local">'Assisted reproductive technologies'</a> below and <a class="local">'Retrieval of sperm'</a> below.)</p><p>Because the majority of men with congenital bilateral absence of the vasa deferentia have heritable genetic mutations associated with cystic fibrosis, these men and their partners who are considering ART to achieve pregnancy should be offered genetic screening and counseling. Screening the female partner may be more cost effective than screening the man. If the female partner does not carry a gene mutation associate with cystic fibrosis, the risk that their progeny will have cystic fibrosis or congenital bilateral absence of the vas deferens is less than 1 in 1500 [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility"</a> and  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility", section on 'Sperm transport disorders'</a> and  <a class="medical medical_review" href="/z/d/html/7453.html" rel="external">"Approach to the male with infertility"</a>.)</p><p class="headingAnchor" id="H3142363178"><span class="h1">ASSISTED REPRODUCTIVE TECHNOLOGIES</span><span class="headingEndMark"> — </span>Assisted reproductive technologies (ART) are commonly used in the United States and other wealthy or industrialized countries. In the United States, ART was used in approximately 1.6 percent of live births in 2014 [<a href="#rid52">52</a>]. ART with intracytoplasmic injection of sperm (ICSI) that has been retrieved from the ejaculate, epididymis, or testis has allowed some infertile men to conceive (eg, men with azoospermia and men with immotile sperm).</p><p>However, ART does not improve rates of live births for all types of male infertility. In a meta-analysis of 10 trials of in vitro fertilization (IVF), ICSI, and intrauterine insemination for couples with male infertility (abnormal sperm parameters), there were no differences in pregnancy or live birth rates between ART and expectant management [<a href="#rid7">7</a>]. Treatment of male factor infertility remains understudied and largely driven by expert opinion and anecdotal experience.</p><p class="headingAnchor" id="H3153549360"><span class="h2">Intrauterine insemination</span><span class="headingEndMark"> — </span>A 2016 systematic review concluded that the data about the overall effectiveness of intrauterine insemination (IUI) for male infertility are inconclusive [<a href="#rid7">7</a>]. The topic of IUI alone or with gonadotropin stimulation of the female partner is discussed elsewhere (see  <a class="medical medical_review" href="/z/d/html/7410.html" rel="external">"Unexplained infertility", section on 'Intrauterine insemination (IUI)'</a>). Because IVF with ICSI is effective, we do not recommend IUI for most couples with male factor infertility.</p><p class="headingAnchor" id="H2690399376"><span class="h2">IVF with ICSI</span><span class="headingEndMark"> — </span>We recommend that a couple whose infertility is primarily due to a male factor should seek treatment in an ART center with experience in IVF with ICSI. IVF describes any process where an egg is fertilized by a sperm outside of the human body. IVF with ICSI has revolutionized the treatment of male factor infertility. This technique involves the direct injection of a single spermatozoon into the cytoplasm of a human oocyte, usually obtained from follicles produced under controlled ovarian hyperstimulation. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a> and  <a class="medical medical_review" href="/z/d/html/3261.html" rel="external">"Intracytoplasmic sperm injection"</a>.)</p><p>If sperm is retrievable from the male partner, the usual overall fertilization rate of ICSI is approximately 60 percent, and the clinical pregnancy rate per cycle is approximately 20 percent, while the multiple pregnancy rate is approximately 30 to 40 percent [<a href="#rid53">53-55</a>]. The ICSI results are not influenced by the cause of the azoospermia.</p><p>In couples with non-male factor infertility, ICSI offers no clinical advantage when compared with conventional IVF. Thus, ICSI should be reserved for those with moderate to severe, male factor infertility. (See  <a class="medical medical_review" href="/z/d/html/3261.html" rel="external">"Intracytoplasmic sperm injection"</a>.)</p><p class="headingAnchor" id="H2295239941"><span class="h3">Retrieval of sperm</span><span class="headingEndMark"> — </span>Sperm from the ejaculate or from a urine sample (in men with severe retrograde ejaculation) can be used for ICSI. ICSI can also be performed successfully using spermatozoa that are obtained from testicular aspiration or biopsies. Many men with nonobstructive azoospermia will have isolated regions of spermatogenesis within the testis; sperm can be retrieved in many men with nonobstructive azoospermia, including men with Klinefelter syndrome and men with longstanding azoospermia after chemotherapy [<a href="#rid5">5,55-65</a>].</p><p>Men undergoing systemic chemotherapy should be considered for referral for sperm banking and sperm cryopreservation; cryopreservation of ejaculated sperm before initiation of chemotherapy ensures higher-quality sperm for ART and avoids surgical sperm retrieval later [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Semen cryopreservation'</a>.)</p><p>ICSI success is dependent on retrieving adequate numbers of spermatozoa or spermatids from the biopsies. Successful pregnancy has been reported even with injection of fresh or cryopreserved immature sperm cells, such as elongated and round spermatids but not with spermatocytes [<a href="#rid66">66,67</a>]. Surgical techniques for retrieval of sperm from the testes include testicular or epididymal aspiration (which can be done with local anesthesia) or multiple open testicular biopsies with testicular sperm extraction (TESE) [<a href="#rid68">68</a>]. TESE is more likely to retrieve sperm for ICSI than testicular aspiration [<a href="#rid6">6</a>]. A modified form of TESE, microTESE, involves microdissection of the testis; using microscopic dissection to identify nests of isolated spermatogenesis to extract with open biopsies is even more effective than TESE for sperm retrieval [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/3261.html" rel="external">"Intracytoplasmic sperm injection", section on 'Sperm retrieval'</a>.)</p><p>When performed by a surgeon who is experienced in microTESE, sperm may extracted in approximately 50 percent of infertile, azoospermic men [<a href="#rid5">5,6,69</a>]. Serum follicle-stimulating hormone (FSH) concentrations may be useful in determining the choice of testicular extraction technique. Higher serum FSH concentrations and smaller testicular volumes generally correlate with impairment of spermatogenesis, and a high serum FSH concentration in a man with azoospermia predicts low probability of retrieving sperm with testicular aspiration or TESE [<a href="#rid70">70-72</a>]. However, many of these men have testicular nests of spermatogenesis that can be visualized and harvested using microTESE [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H1335491010"><span class="h3">Pregnancy outcome with ICSI</span><span class="headingEndMark"> — </span>The success of ICSI to permit men with infertility related to genetic disorders to conceive has raised concerns about an increased risk of chromosomal abnormalities and congenital malformations in live births following ICSI. Children conceived by IVF and/or ICSI are at increased risk for birth defects, but the absolute risk is very low. For example, Klinefelter syndrome is a common genetic cause of male infertility, but the risk of a transmitting man with Klinefelter syndrome having a son with a karyotype associated with Klinefelter syndrome (eg, XXY karyotype) appears to be low [<a href="#rid5">5,65,73</a>]. These data are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3261.html" rel="external">"Intracytoplasmic sperm injection"</a> and  <a class="medical medical_review" href="/z/d/html/6788.html" rel="external">"Assisted reproductive technology: Pregnancy and maternal outcomes"</a>.)</p><p class="headingAnchor" id="H4278190633"><span class="h3">Genetic counseling and testing</span><span class="headingEndMark"> — </span>Although the absolute risk of genetic abnormalities is low for live births after ICSI for male factor infertility, genetic counseling and testing should be offered before ICSI in the following settings: (1) karyotyping for infertile men with sperm concentrations &lt;10 million/mL; (2) testing for Y chromosomal microdeletion for infertile men with sperm concentrations &lt;5 million/mL; (3) screening for gene mutations associated with cystic fibrosis for infertile men with congenital absence of bilateral vasa deferentia [<a href="#rid29">29,74</a>]. (See <a class="local">'Congenital bilateral absence of the vasa deferentia'</a> above.)</p><p class="headingAnchor" id="H454532711"><span class="h3">ART with donor semen</span><span class="headingEndMark"> — </span>The time-tested method of ART with donor semen has a very high success rate in apparently normal female recipients: 50 percent pregnancy rate with six cycles of insemination. Children born from pregnancies resulting from donor insemination grow and develop normally, both physically and psychologically [<a href="#rid75">75</a>]. This alternative, together with adoption and childlessness, should be offered to all couples with male factor infertility. (See  <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">"Donor insemination"</a>.)</p><p class="headingAnchor" id="H2379732247"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115208.html" rel="external">"Society guideline links: Male infertility or hypogonadism"</a>.)</p><p class="headingAnchor" id="H785859332"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15425.html" rel="external">"Patient education: Male infertility (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2180.html" rel="external">"Patient education: Treatment of male infertility (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H978425876"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest assessment and treatment of the female partner before or concurrent with the male partner of an infertile couple. (See <a class="local">'Concurrent male and female infertility'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small minority of infertile men have medically or surgically reversible causes of infertility. Assisted reproductive technology (ART) is the only potentially effective treatment for most causes of male infertility. (See <a class="local">'Assisted reproductive technologies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest gonadotropin replacement therapy for induction of spermatogenesis in men whose infertility results from secondary (hypogonadotropic) hypogonadism (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Secondary (hypogonadotropic) hypogonadism: Induction of spermatogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For men with secondary (hypogonadotropic) hypogonadism due to a prolactin adenoma, we suggest dopamine agonist therapy, usually <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">cabergoline</a>, as this typically restores spermatogenesis and fertility. In men with prolactin macroadenomas, lowering the serum prolactin concentration and shrinking the adenoma may not be sufficient to increase the <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentration and sperm count (because of permanent damage to the gonadotroph cells). In this case, we start gonadotropin therapy for induction of spermatogenesis. (See <a class="local">'Hyperprolactinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest against the use of <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate, aromatase inhibitors, or gonadotropin therapy for secondary (hypogonadotropic) hypogonadism, idiopathic dysspermatogenesis, or idiopathic male infertility (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Medical therapies to increase circulating gonadotropin concentrations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest varicocele repair only in infertile men with abnormal semen analyses and large, grade 3 varicoceles. (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) Surgical repair is also reasonable in men (with or without infertility) with large varicoceles causing symptoms. We do not recommend varicocele surgery in infertile men with small varicoceles that are not palpable. (See <a class="local">'Surgical repair of varicocele'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If sperm are retrievable from testis, epididymis, or ejaculate, we suggest ART as it may result in live births independent of the cause of infertility (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Assisted reproductive technologies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intracytoplasmic injection of spermatozoa (ICSI) into the oocyte is the most effective and common technique used for patients with male factor infertility. (See <a class="local">'IVF with ICSI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counseling and testing should be offered to many couples with male factor infertility prior to use of ICSI and ART. (See <a class="local">'Genetic counseling and testing'</a> above.)</p><p></p><p class="headingAnchor" id="H2298254550"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ronald Swerdloff, MD, Christina Wang, MD, and Stephanie Page, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">GUTTMACHER AF. Factors affecting normal expectancy of conception. J Am Med Assoc 1956; 161:855.</a></li><li><a class="nounderline abstract_t">Jungwirth A, Giwercman A, Tournaye H, et al. European Association of Urology guidelines on Male Infertility: the 2012 update. Eur Urol 2012; 62:324.</a></li><li><a class="nounderline abstract_t">World Health Organization. Towards more objectivity in diagnosis and management of male infertility. Int J Androl 1987; 7(Suppl):1.</a></li><li class="breakAll">Baker HWG. Development of clinical trials in male infertility research. In: Perspectives in Andrology, Sario M (Ed), Raven Press, New York 1989. p.367.</li><li><a class="nounderline abstract_t">Schiff JD, Palermo GD, Veeck LL, et al. Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome. J Clin Endocrinol Metab 2005; 90:6263.</a></li><li><a class="nounderline abstract_t">Bernie AM, Mata DA, Ramasamy R, Schlegel PN. Comparison of microdissection testicular sperm extraction, conventional testicular sperm extraction, and testicular sperm aspiration for nonobstructive azoospermia: a systematic review and meta-analysis. Fertil Steril 2015; 104:1099.</a></li><li><a class="nounderline abstract_t">Cissen M, Bensdorp A, Cohlen BJ, et al. Assisted reproductive technologies for male subfertility. Cochrane Database Syst Rev 2016; 2:CD000360.</a></li><li><a class="nounderline abstract_t">Zini A, Bach PV, Al-Malki AH, Schlegel PN. Use of testicular sperm for ICSI in oligozoospermic couples: how far should we go? Hum Reprod 2017; 32:7.</a></li><li><a class="nounderline abstract_t">Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter's syndrome. Lancet 2004; 364:273.</a></li><li><a class="nounderline abstract_t">Al-Ali BM, Marszalek M, Shamloul R, et al. Clinical parameters and semen analysis in 716 Austrian patients with varicocele. Urology 2010; 75:1069.</a></li><li><a class="nounderline abstract_t">Kim HH, Goldstein M. Adult varicocele. Curr Opin Urol 2008; 18:608.</a></li><li><a class="nounderline abstract_t">Kroese AC, de Lange NM, Collins J, Evers JL. Surgery or embolization for varicoceles in subfertile men. Cochrane Database Syst Rev 2012; 10:CD000479.</a></li><li class="breakAll">World Health Organization. WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction, 4th Ed., Cambridge University Press, Cambridge 1999.</li><li><a class="nounderline abstract_t">Eley A, Pacey AA, Galdiero M, et al. Can Chlamydia trachomatis directly damage your sperm? Lancet Infect Dis 2005; 5:53.</a></li><li><a class="nounderline abstract_t">Schuppe HC, Pilatz A, Hossain H, et al. Urogenital Infection as a Risk Factor for Male Infertility. Dtsch Arztebl Int 2017; 114:339.</a></li><li><a class="nounderline abstract_t">Hamada A, Agarwal A, Sharma R, et al. Empirical treatment of low-level leukocytospermia with doxycycline in male infertility patients. Urology 2011; 78:1320.</a></li><li><a class="nounderline abstract_t">Showell MG, Mackenzie-Proctor R, Brown J, et al. Antioxidants for male subfertility. Cochrane Database Syst Rev 2014; :CD007411.</a></li><li><a class="nounderline abstract_t">Vandekerckhove P, Lilford R, Vail A, Hughes E. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 2000; :CD000151.</a></li><li><a class="nounderline abstract_t">A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. World Health Organization. Int J Androl 1992; 15:299.</a></li><li><a class="nounderline abstract_t">Foresta C, Bettella A, Garolla A, et al. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005; 84:654.</a></li><li><a class="nounderline abstract_t">Chua ME, Escusa KG, Luna S, et al. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology 2013; 1:749.</a></li><li><a class="nounderline abstract_t">Kim HH, Schlegel PN. Endocrine manipulation in male infertility. Urol Clin North Am 2008; 35:303.</a></li><li><a class="nounderline abstract_t">Cavallini G, Biagiotti G, Bolzon E. Multivariate analysis to predict letrozole efficacy in improving sperm count of non-obstructive azoospermic and cryptozoospermic patients: a pilot study. Asian J Androl 2013; 15:806.</a></li><li><a class="nounderline abstract_t">Schlegel PN. Aromatase inhibitors for male infertility. Fertil Steril 2012; 98:1359.</a></li><li><a class="nounderline abstract_t">Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013; 369:1011.</a></li><li><a class="nounderline abstract_t">Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 2013; :CD005071.</a></li><li><a class="nounderline abstract_t">Kandeel FR, Swerdloff RS. Role of temperature in regulation of spermatogenesis and the use of heating as a method for contraception. Fertil Steril 1988; 49:1.</a></li><li><a class="nounderline abstract_t">Lue YH, Hikim AP, Swerdloff RS, et al. Single exposure to heat induces stage-specific germ cell apoptosis in rats: role of intratesticular testosterone on stage specificity. Endocrinology 1999; 140:1709.</a></li><li><a class="nounderline abstract_t">Anawalt BD. Approach to male infertility and induction of spermatogenesis. J Clin Endocrinol Metab 2013; 98:3532.</a></li><li><a class="nounderline abstract_t">Shoshany O, Abhyankar N, Mufarreh N, et al. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men. Fertil Steril 2017; 107:589.</a></li><li><a class="nounderline abstract_t">Helo S, Ellen J, Mechlin C, et al. A Randomized Prospective Double-Blind Comparison Trial of Clomiphene Citrate and Anastrozole in Raising Testosterone in Hypogonadal Infertile Men. J Sex Med 2015; 12:1761.</a></li><li><a class="nounderline abstract_t">Stokes VJ, Anderson RA, George JT. How does obesity affect fertility in men - and what are the treatment options? Clin Endocrinol (Oxf) 2015; 82:633.</a></li><li><a class="nounderline abstract_t">Ribeiro MA, Gameiro LF, Scarano WR, et al. Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials. JBRA Assist Reprod 2016; 20:82.</a></li><li><a class="nounderline abstract_t">Gunn DD, Bates GW. Evidence-based approach to unexplained infertility: a systematic review. Fertil Steril 2016; 105:1566.</a></li><li><a class="nounderline abstract_t">Wang C, McDonald V, Leung A, et al. Effect of increased scrotal temperature on sperm production in normal men. Fertil Steril 1997; 68:334.</a></li><li><a class="nounderline abstract_t">Munkelwitz R, Gilbert BR. Are boxer shorts really better? A critical analysis of the role of underwear type in male subfertility. J Urol 1998; 160:1329.</a></li><li><a class="nounderline abstract_t">Oldereid NB, Rui H, Purvis K. Life styles of men in barren couples and their relationship to sperm quality. Int J Fertil 1992; 37:343.</a></li><li><a class="nounderline abstract_t">Safarinejad MR. Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia 2011; 43:38.</a></li><li><a class="nounderline abstract_t">Martínez-Soto JC, Domingo JC, Cordobilla B, et al. Dietary supplementation with docosahexaenoic acid (DHA) improves seminal antioxidant status and decreases sperm DNA fragmentation. Syst Biol Reprod Med 2016; 62:387.</a></li><li><a class="nounderline abstract_t">González-Ravina C, Aguirre-Lipperheide M, Pinto F, et al. Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function. Reprod Biol 2018; 18:282.</a></li><li><a class="nounderline abstract_t">Jensen TK, Priskorn L, Holmboe SA, et al. Associations of Fish Oil Supplement Use With Testicular Function in Young Men. JAMA Netw Open 2020; 3:e1919462.</a></li><li><a class="nounderline abstract_t">Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995; 333:1517.</a></li><li><a class="nounderline abstract_t">Mehta A, Sigman M. Management of the dry ejaculate: a systematic review of aspermia and retrograde ejaculation. Fertil Steril 2015; 104:1074.</a></li><li><a class="nounderline abstract_t">Jefferys A, Siassakos D, Wardle P. The management of retrograde ejaculation: a systematic review and update. Fertil Steril 2012; 97:306.</a></li><li class="breakAll">Smith JF, Walsh TJ, Turek PJ. Ejaculatory duct obstruction. Urol Clin N Am 2008; 35:221.</li><li><a class="nounderline abstract_t">Majzoub A, Tadros NN, Polackwich AS, et al. Vasectomy reversal semen analysis: new reference ranges predict pregnancy. Fertil Steril 2017; 107:911.</a></li><li><a class="nounderline abstract_t">Nagler HM, Jung H. Factors predicting successful microsurgical vasectomy reversal. Urol Clin North Am 2009; 36:383.</a></li><li><a class="nounderline abstract_t">Belker AM, Thomas AJ Jr, Fuchs EF, et al. Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group. J Urol 1991; 145:505.</a></li><li><a class="nounderline abstract_t">Robb P, Sandlow JI. Cost-effectiveness of vasectomy reversal. Urol Clin North Am 2009; 36:391.</a></li><li><a class="nounderline abstract_t">Shridharani A, Sandlow JI. Vasectomy reversal versus IVF with sperm retrieval: which is better? Curr Opin Urol 2010; 20:503.</a></li><li><a class="nounderline abstract_t">de Kretser DM. Male infertility. Lancet 1997; 349:787.</a></li><li><a class="nounderline abstract_t">Sunderam S, Kissin DM, Crawford SB, et al. Assisted Reproductive Technology Surveillance - United States, 2014. MMWR Surveill Summ 2017; 66:1.</a></li><li><a class="nounderline abstract_t">Schlegel PN, Girardi SK. Clinical review 87: In vitro fertilization for male factor infertility. J Clin Endocrinol Metab 1997; 82:709.</a></li><li><a class="nounderline abstract_t">Palermo GD, Cohen J, Alikani M, et al. Intracytoplasmic sperm injection: a novel treatment for all forms of male factor infertility. Fertil Steril 1995; 63:1231.</a></li><li><a class="nounderline abstract_t">Tarlatzis BC, Bili H. Intracytoplasmic sperm injection. Survey of world results. Ann N Y Acad Sci 2000; 900:336.</a></li><li><a class="nounderline abstract_t">Gnoth C, Maxrath B, Skonieczny T, et al. Final ART success rates: a 10 years survey. Hum Reprod 2011; 26:2239.</a></li><li><a class="nounderline abstract_t">Reubinoff BE, Abeliovich D, Werner M, et al. A birth in non-mosaic Klinefelter's syndrome after testicular fine needle aspiration, intracytoplasmic sperm injection and preimplantation genetic diagnosis. Hum Reprod 1998; 13:1887.</a></li><li><a class="nounderline abstract_t">Staessen C, Tournaye H, Van Assche E, et al. PGD in 47,XXY Klinefelter's syndrome patients. Hum Reprod Update 2003; 9:319.</a></li><li><a class="nounderline abstract_t">Mulhall JP, Reijo R, Alagappan R, et al. Azoospermic men with deletion of the DAZ gene cluster are capable of completing spermatogenesis: fertilization, normal embryonic development and pregnancy occur when retrieved testicular spermatozoa are used for intracytoplasmic sperm injection. Hum Reprod 1997; 12:503.</a></li><li><a class="nounderline abstract_t">Tournaye H, Staessen C, Liebaers I, et al. Testicular sperm recovery in nine 47,XXY Klinefelter patients. Hum Reprod 1996; 11:1644.</a></li><li><a class="nounderline abstract_t">Chan PT, Palermo GD, Veeck LL, et al. Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer 2001; 92:1632.</a></li><li><a class="nounderline abstract_t">Damani MN, Master V, Meng MV, et al. Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol 2002; 20:930.</a></li><li><a class="nounderline abstract_t">Revel A, Haimov-Kochman R, Porat A, et al. In vitro fertilization-intracytoplasmic sperm injection success rates with cryopreserved sperm from patients with malignant disease. Fertil Steril 2005; 84:118.</a></li><li><a class="nounderline abstract_t">Hsiao W, Stahl PJ, Osterberg EC, et al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience. J Clin Oncol 2011; 29:1607.</a></li><li><a class="nounderline abstract_t">Ramasamy R, Ricci JA, Palermo GD, et al. Successful fertility treatment for Klinefelter's syndrome. J Urol 2009; 182:1108.</a></li><li><a class="nounderline abstract_t">Tesarik J, Mendoza C, Testart J. Viable embryos from injection of round spermatids into oocytes. N Engl J Med 1995; 333:525.</a></li><li><a class="nounderline abstract_t">Al-Hasani S, Ludwig M, Palermo I, et al. Intracytoplasmic injection of round and elongated spermatids from azoospermic patients: results and review. Hum Reprod 1999; 14 Suppl 1:97.</a></li><li><a class="nounderline abstract_t">Donoso P, Tournaye H, Devroey P. Which is the best sperm retrieval technique for non-obstructive azoospermia? A systematic review. Hum Reprod Update 2007; 13:539.</a></li><li><a class="nounderline abstract_t">Schlegel PN. Nonobstructive azoospermia: a revolutionary surgical approach and results. Semin Reprod Med 2009; 27:165.</a></li><li><a class="nounderline abstract_t">Ishikawa T. Surgical recovery of sperm in non-obstructive azoospermia. Asian J Androl 2012; 14:109.</a></li><li><a class="nounderline abstract_t">Bromage SJ, Falconer DA, Lieberman BA, et al. Sperm retrieval rates in subgroups of primary azoospermic males. Eur Urol 2007; 51:534.</a></li><li><a class="nounderline abstract_t">Madani AH, Falahatkar S, Heidarzadeh A, et al. Sensitivity and specificity of serum FSH and testis size in predicting the existence of spermatogenesis in azoospermic infertile men. Andrologia 2012; 44:205.</a></li><li><a class="nounderline abstract_t">Greco E, Scarselli F, Minasi MG, et al. Birth of 16 healthy children after ICSI in cases of nonmosaic Klinefelter syndrome. Hum Reprod 2013; 28:1155.</a></li><li><a class="nounderline abstract_t">McLachlan RI, O'Bryan MK. Clinical Review#: State of the art for genetic testing of infertile men. J Clin Endocrinol Metab 2010; 95:1013.</a></li><li><a class="nounderline abstract_t">Kovacs GT, Mushin D, Kane H, Baker HW. A controlled study of the psycho-social development of children conceived following insemination with donor semen. Hum Reprod 1993; 8:788.</a></li></ol></div><div id="topicVersionRevision">Topic 7452 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13319020" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Factors affecting normal expectancy of conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22591628" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : European Association of Urology guidelines on Male Infertility: the 2012 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Towards more objectivity in diagnosis and management of male infertility</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Towards more objectivity in diagnosis and management of male infertility</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131585" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Success of testicular sperm extraction [corrected] and intracytoplasmic sperm injection in men with Klinefelter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26263080" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of microdissection testicular sperm extraction, conventional testicular sperm extraction, and testicular sperm aspiration for nonobstructive azoospermia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26915339" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Assisted reproductive technologies for male subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816927" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of testicular sperm for ICSI in oligozoospermic couples: how far should we go?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262106" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Klinefelter's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20138656" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical parameters and semen analysis in 716 Austrian patients with varicocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18832947" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Adult varicocele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076888" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Surgery or embolization for varicoceles in subfertile men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076888" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Surgery or embolization for varicoceles in subfertile men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15620561" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Can Chlamydia trachomatis directly damage your sperm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28597829" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Urogenital Infection as a Risk Factor for Male Infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22137697" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Empirical treatment of low-level leukocytospermia with doxycycline in male infertility patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25504418" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antioxidants for male subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796497" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clomiphene or tamoxifen for idiopathic oligo/asthenospermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516979" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. World Health Organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169399" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23970453" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18423250" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Endocrine manipulation in male infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24121976" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multivariate analysis to predict letrozole efficacy in improving sperm count of non-obstructive azoospermic and cryptozoospermic patients: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23103016" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Aromatase inhibitors for male infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24024838" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Gonadal steroids and body composition, strength, and sexual function in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23970458" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gonadotrophins for idiopathic male factor subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275550" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Role of temperature in regulation of spermatogenesis and the use of heating as a method for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10098507" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Single exposure to heat induces stage-specific germ cell apoptosis in rats: role of intratesticular testosterone on stage specificity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24014811" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Approach to male infertility and induction of spermatogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28069178" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26176805" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A Randomized Prospective Double-Blind Comparison Trial of Clomiphene Citrate and Anastrozole in Raising Testosterone in Hypogonadal Infertile Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25138694" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : How does obesity affect fertility in men - and what are the treatment options?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27244767" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26902860" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Evidence-based approach to unexplained infertility: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240266" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of increased scrotal temperature on sperm production in normal men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751347" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Are boxer shorts really better? A critical analysis of the role of underwear type in male subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1360454" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Life styles of men in barren couples and their relationship to sperm quality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21219381" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792396" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dietary supplementation with docosahexaenoic acid (DHA) improves seminal antioxidant status and decreases sperm DNA fragmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29934046" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31951274" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Associations of Fish Oil Supplement Use With Testicular Function in Young Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477165" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26432530" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Management of the dry ejaculate: a systematic review of aspermia and retrograde ejaculation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177462" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The management of retrograde ejaculation: a systematic review and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177462" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The management of retrograde ejaculation: a systematic review and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283266" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Vasectomy reversal semen analysis: new reference ranges predict pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643240" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Factors predicting successful microsurgical vasectomy reversal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1997700" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Results of 1,469 microsurgical vasectomy reversals by the Vasovasostomy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643241" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cost-effectiveness of vasectomy reversal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20852426" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vasectomy reversal versus IVF with sperm retrieval: which is better?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9074589" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Male infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28182605" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Assisted Reproductive Technology Surveillance - United States, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062469" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical review 87: In vitro fertilization for male factor infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7750593" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intracytoplasmic sperm injection: a novel treatment for all forms of male factor infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10818422" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Intracytoplasmic sperm injection. Survey of world results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21659314" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Final ART success rates: a 10 years survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740443" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A birth in non-mosaic Klinefelter's syndrome after testicular fine needle aspiration, intracytoplasmic sperm injection and preimplantation genetic diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12926526" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : PGD in 47,XXY Klinefelter's syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9130751" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Azoospermic men with deletion of the DAZ gene cluster are capable of completing spermatogenesis: fertilization, normal embryonic development and pregnancy occur when retrieved testicular spermatozoa are used for intracytoplasmic sperm injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8921109" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Testicular sperm recovery in nine 47,XXY Klinefelter patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745242" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844813" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009166" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : In vitro fertilization-intracytoplasmic sperm injection success rates with cryopreserved sperm from patients with malignant disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21402606" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19616796" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Successful fertility treatment for Klinefelter's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7623897" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Viable embryos from injection of round spermatids into oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573027" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Intracytoplasmic injection of round and elongated spermatids from azoospermic patients: results and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17895238" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Which is the best sperm retrieval technique for non-obstructive azoospermia? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19247918" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Nonobstructive azoospermia: a revolutionary surgical approach and results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22120931" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Surgical recovery of sperm in non-obstructive azoospermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16997455" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sperm retrieval rates in subgroups of primary azoospermic males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21790709" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sensitivity and specificity of serum FSH and testis size in predicting the existence of spermatogenesis in azoospermic infertile men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23493114" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Birth of 16 healthy children after ICSI in cases of nonmosaic Klinefelter syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089613" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical Review#: State of the art for genetic testing of infertile men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8314978" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A controlled study of the psycho-social development of children conceived following insemination with donor semen.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
